The short answer
CJC-1295 is a synthetic growth-hormone-releasing hormone analogue based on the first 29 residues of human GHRH, carrying four substitutions that resist enzymatic cleavage. It exists in two forms: with a Drug Affinity Complex at 3647.2 Da, and without it at 3367.9 Da.
Key facts
- Basis
- GRF(1-29), residues 1-29 of human GHRH
- Length
- 29 residues, C-terminal amide
- Substitutions
- D-Ala2, Gln8, Ala15, Leu27
- With DAC
- 3647.2 Da, PubChem CID 91971820
- Without DAC
- 3367.9 Da, CID 56841945, CAS 863288-34-0
- DAC adds
- 279.3 Da
- Developer
- ConjuChem
What it is built from
Human growth-hormone-releasing hormone is 44 residues, and its biological activity resides in the first 29, the fragment known as GRF(1-29), also marketed as sermorelin. The name is written CJC-1295, CJC 1295 or cjc1295 interchangeably; the real distinction is with DAC versus without. CJC-1295 takes that fragment and substitutes four residues to slow enzymatic degradation. Despite frequent description as a 30-residue peptide, it is 29 residues terminating in an amide; PubChem's systematic name enumerates exactly 29.
The four substitutions and what each does
D-alanine at position 2 is the important one: DPP-4 cleaves after position 2 in GHRH, and a D-amino acid there is not a substrate. Gln8, Ala15 and Leu27 address other degradation points. The substitutions also remove the methionine present in native GRF(1-29), which is why Mod GRF's formula (C152H252N44O42) contains no sulfur where sermorelin's (C149H246N44O42S) does.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
The two forms, and the masses that separate them
With DAC, the peptide carries a maleimidopropionic acid linker that binds covalently to cysteine-34 of serum albumin, giving a half-life measured in days. Without DAC (the form usually called Modified GRF (1-29)), it clears in roughly half an hour. They differ by 279.3 Da, which is the linker. Supplying the mass alongside the name is the most reliable way to distinguish them.
Why the naming is so confused
PubChem record CID 56841945 carries both 'CJC 1295 with DAC' and 'CJC-1295-no DAC acetate' among its synonyms. The authoritative chemical database is internally inconsistent on this compound, so secondary sources inherit the confusion rather than causing it. This is why mass rather than name is the field to check.
Where it came from
CJC-1295 was developed by ConjuChem, and the DAC technology was the focus of the programme: a general approach to extending peptide half-life by covalent albumin attachment, applied here to a GHRH analogue. Teichman and colleagues reported on prolonged GH and IGF-I stimulation in healthy adults in the Journal of Clinical Endocrinology and Metabolism in 2006.
Regulatory position
CJC-1295 holds no marketing authorisation from the MHRA, EMA or FDA. Growth-hormone secretagogues are prohibited in sport under the World Anti-Doping Agency list. It is supplied here for laboratory research only.
Frequently asked questions
Is CJC-1295 29 or 30 residues?
29. GRF(1-29) means residues 1 to 29, and the peptide terminates in an amide rather than a thirtieth residue. The 30-residue description is a common error.
What is the molecular weight?
3647.2 Da with DAC, 3367.9 Da without. The 279.3 Da difference is the DAC linker.
Why do sources disagree about which form is which?
PubChem itself lists contradictory synonyms on one record. Comparing molecular weight is more reliable than comparing names.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedTeichman SL et al., Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / DAC:GRF (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubMedIonescu M & Frohman LA, Pulsatile GH secretion persists during continuous stimulation. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- CJC-1295 With and Without DAC3647.2 Da against 3367.9 Da - a 279.3 Da linker separating a week-long half-life from about thirty minutes. How to tell which form you have.
- Half-Life: Why a Covalent Bond Changes EverythingMinutes for native GHRH, about thirty for Mod GRF, days for the DAC form. Each step is a specific chemical intervention against a specific clearance route.
- What Is Ipamorelin? Sequence, Receptor and SelectivityIpamorelin is a five-residue ghrelin receptor agonist, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described as the first selective growth hormone secretagogue.
- How CJC-1295 Works as a GHRH AnalogueCJC-1295 agonises the GHRH receptor on pituitary somatotrophs. Why the substitutions matter and what continuous versus pulsatile stimulation implies.
- Why These Two Are Studied TogetherTwo receptors, one output. The mechanistic rationale for pairing a GHRH analogue with a ghrelin receptor agonist - and what would be needed to test it.